The Patent Finder

Compositions and Methods for Modulation of SMN2 Splicing in a Subject (2015)

Isis Pharmaceuticals, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,717,750Compositions and Methods for Modulation of SMN2 Splicing in a Subject
In force
 · Medium confidence
Isis Pharmaceuticals, Inc.In forceMedium confidence
Application 15/892,560Compositions and Methods for Modulation of SMN2 Splicing in a Subject
Abandoned
Abandoned Jan 6, 2020
Biogen Ma Inc.AbandonedAbandoned Jan 6, 2020
Application 16/708,739Compositions and Methods for Modulation of SMN2 Splicing in a Subject
Abandoned
Abandoned Oct 19, 2021
Biogen Ma Inc.AbandonedAbandoned Oct 19, 2021
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Isis Pharmaceuticals, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited